The combination of JAK2 inhibitors with epigenetic modulators, such as histone deacetylase inhibitors (HDAC inhibitors) or DNA methyltransferase inhibitors (DNMT inhibitors), offers the potential to reverse the epigenetic alterations that contribute to leukemia progression and resistance. This evidence concerns the gene HDAC9 and leukemia.